Zenas BioPharma, Inc.

Healthcare · Biotechnology · United States

Last price 28.76 USD (Oct 29, 2026, 4:00 PM EDT) · Market cap 1.87B

Overview · Financial statements · Key statistics · Dividends · Company profile · Price history · Reports

Zenas BioPharma, Inc., a clinical-stage biopharma company, engages in the development and commercialization of transformative immunology-based therapies. Its lead product candidate is obexelimab, a bifunctional monoclonal antibody designed to bind CD19 and FcγRIIb for the treatment of various I&I diseases and various indications, including immunoglobulin G4-related disease, multiple sclerosis, and systemic lupus erythematosus. The company develops ZB002, an anti-TNFa monoclonal antibody; ZB004, a CTLA-4-Ig fusion protein designed to have an ext...